On 4/16/24, Intra-Cellular Therapies Inc (NASDAQ: ITCI) stock enjoyed a major increase of 23.3%, closing at $79.84. Moreover, trading volume in this advance was exceptionally high at 867% of normal. The stock has been exceptionally strong relative to the market over the last nine months and has risen 17.9% during the last week.
Current PriceTarget Research Rating
Reflecting future returns on capital that are forecasted to be in line with the cost of capital, ITCI is expected to continue to be Value Creation neutral.
Intra-Cellular Therapies has a current Value Trend Rating of D (Negative). The Value Trend Rating reflects very contradictory signals from PTR’s two proprietary measures of a stock’s attractiveness. Intra-Cellular Therapies has a very low Appreciation Score of 9 but a good Power Rating of 71, producing the Negative Value Trend Rating.
Rating Review
In light of this very positive price change we are reviewing our current Overall Rating of D. This review will be completed in the next several days.
Be the first to comment